DESIGN, OPTIMIZATION AND EVALUATION OF BUCCAL DRUG DELIVERY SYSTEM OF PROPRANOLOL FOR HYPERTENSION TREATMENT

The main objectives of the present study were to design, optimization and evaluation of buccal drug delivery system of propranolol for hypertension treatment. Propranolol is non-selective β-adrenergic blockers. It shows first-pass metabolism so its bioavailability is decreased and its absolute bioavailability is only about 26%. The buccal tablets of propranolol formulated, by using different mucoadhesive polymers such as sodium crosscarmilose sodium, PVP K30, and HPMC K15M. F8 was containing 18.18% PVPK30, 10.90% HPMC K15M showed desired drug release within 6 h to above batches. The dissolution profile of formulated batch F1 to F8 at the end of 6 h was found in the range of 83.03 to 94.69% in phosphate buffer pH 6.8. From the results, it was found that formulation F8 was shown most similar dissolution profile because the similarity value was found to be above 90%. The swelling index was found higher in formulation F9 80.15% swelling observed because of higher concentration of PVP K30 and HPMC K15M. The results indicate that out of two bioadhesive polymers PVP k 30 along with HPMC K15M in different concentration with fraction batches code F1 to F9 having PVP K30 have shown more bioadhesive strength than HPMC K15M. Statistical optimization of propranolol tablet was done by design expert software, version 8.0.7.1. No significant changes were observed in the physical appearance, mucoadhesive strength and drug content of the formulations kept both at room temperature (RT) and accelerated conditions (45 °C, 75% RH) for 1 month.